Thrivent Financial For Lutherans lessened its holdings in shares of Humana Inc (NYSE:HUM) by 64.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,829 shares of the insurance provider’s stock after selling 10,701 shares during the period. Thrivent Financial For Lutherans’ holdings in Humana were worth $1,446,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in HUM. Wells Fargo & Company MN grew its holdings in shares of Humana by 10.0% during the 3rd quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock worth $402,799,000 after acquiring an additional 150,173 shares during the period. Commonwealth Bank of Australia grew its holdings in shares of Humana by 3.9% during the 3rd quarter. Commonwealth Bank of Australia now owns 21,112 shares of the insurance provider’s stock worth $5,138,000 after acquiring an additional 796 shares during the period. Prudential Financial Inc. grew its holdings in shares of Humana by 53.6% during the 3rd quarter. Prudential Financial Inc. now owns 378,133 shares of the insurance provider’s stock worth $92,125,000 after acquiring an additional 131,990 shares during the period. Icon Advisers Inc. Co. grew its holdings in shares of Humana by 22.7% during the 3rd quarter. Icon Advisers Inc. Co. now owns 5,400 shares of the insurance provider’s stock worth $1,316,000 after acquiring an additional 1,000 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in shares of Humana by 10.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock worth $356,960,000 after acquiring an additional 142,706 shares during the period. Institutional investors own 96.36% of the company’s stock.
A number of research analysts have weighed in on HUM shares. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 19th. Cowen reiterated a “buy” rating and set a $285.00 target price on shares of Humana in a report on Wednesday, December 13th. Cantor Fitzgerald reiterated a “hold” rating and set a $230.00 target price on shares of Humana in a report on Tuesday, December 5th. Jefferies Group upgraded Humana from a “hold” rating to a “buy” rating and set a $221.00 target price on the stock in a report on Friday, January 12th. Finally, Oppenheimer upped their target price on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $270.47.
In related news, SVP Cynthia H. Zipperle sold 1,196 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $273.33, for a total value of $326,902.68. Following the transaction, the senior vice president now directly owns 7,771 shares of the company’s stock, valued at approximately $2,124,047.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 14,075 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the transaction, the chief executive officer now directly owns 113,896 shares in the company, valued at $31,243,950.72. The disclosure for this sale can be found here. Insiders sold a total of 31,660 shares of company stock worth $8,668,218 over the last ninety days. 0.60% of the stock is currently owned by insiders.
Shares of Humana stock opened at $270.81 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85. Humana Inc has a 12-month low of $203.48 and a 12-month high of $293.35. The company has a market capitalization of $37,670.43, a P/E ratio of 23.41, a PEG ratio of 1.48 and a beta of 0.95.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same period in the previous year, the firm posted $2.34 EPS. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. research analysts predict that Humana Inc will post 13.84 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a $0.50 dividend. The ex-dividend date is Wednesday, March 28th. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.74%. Humana’s dividend payout ratio is 9.59%.
Humana declared that its board has initiated a stock repurchase plan on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.